What’s Happening With Addex Therapeutics Shares Today
Addex Therapeutics Ltd (NASDAQ:ADXN) shares are surging after reducing the nominal value of its issued, authorized, and conditional share…
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating…
Amazon Bets Almost $4B On Primary Health Care Provider To Deepen Its Presence In Healthcare
Amazon.com Inc (NASDAQ:AMZN) will acquire 1life Healthcare Inc (One Medical) (NASDAQ:ONEM) for $18 a share in an all-cash deal valuing the…
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recursion Gains European Commission Orphan Drug Status For Rare Tumor Candidate
Recursion (NASDAQ: RXRX) received Orphan Drug Designation for REC-4881 from the European Commission towards the potential treatment of familial adenomatous polyposis (FAP).
IQVIA’s Q2 Earnings Surpass Expectations; Forex Hits FY22 Top-Line Forecast
IQVIA Holdings Inc (NYSE:IQV) posted Q2 sales of $3.54 billion, up 3% Y/Y on a reported basis and 7.1% at…
Tabula Rasa Sees Better Than Expected Q2 Sales, Just As Investor Calls For Removal Of Top Executives
Tabula Rasa HealthCare Inc (NASDAQ:TRHC) expects Q2 sales of $72 – $73 million, exceeding the prior guidance range of $66…
X4 Pharma To Stop Further Work On Oncology Programs, Looks For Partner(s)
X4 Pharmaceuticals Inc (NASDAQ:XFOR) updated its strategic priorities that include streamlining resources to focus on advancing its lead candidate, mavorixafor, in…
Danaher Easily Beats Q2 Street View With Growth From Base Business; FY22 Outlook Unchanged
Danaher Corp (NYSE:DHR) has logged Q2 FY22 adjusted EPS of $2.76, up 12% Y/Y, surpassing the estimate of $2.35. Sales…
Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection
Assembly Biosciences Inc (NASDAQ:ASMB) will stop working on its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes its next-gen core…